EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance

Stefano Fogli, Beatrice Polini, Marzia Del Re, Iacopo Petrini, Antonio Passaro, Stefania Crucitta, Eleonora Rofi, Romano Danesi

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.

Original languageEnglish
Pages (from-to)727-740
Number of pages14
JournalPharmacogenomics
Volume19
Issue number8
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Clinical Pharmacology
Non-Small Cell Lung Carcinoma
Pharmacology
Therapeutics
Treatment Failure
Drug Resistance
Pharmaceutical Preparations
Uncertainty
Neoplasms

Keywords

  • drug resistance
  • EGFR TKIs
  • non-small-cell lung cancer
  • pharmacology

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

EGFR-TKIs in non-small-cell lung cancer : Focus on clinical pharmacology and mechanisms of resistance. / Fogli, Stefano; Polini, Beatrice; Del Re, Marzia; Petrini, Iacopo; Passaro, Antonio; Crucitta, Stefania; Rofi, Eleonora; Danesi, Romano.

In: Pharmacogenomics, Vol. 19, No. 8, 01.01.2018, p. 727-740.

Research output: Contribution to journalReview article

Fogli, Stefano ; Polini, Beatrice ; Del Re, Marzia ; Petrini, Iacopo ; Passaro, Antonio ; Crucitta, Stefania ; Rofi, Eleonora ; Danesi, Romano. / EGFR-TKIs in non-small-cell lung cancer : Focus on clinical pharmacology and mechanisms of resistance. In: Pharmacogenomics. 2018 ; Vol. 19, No. 8. pp. 727-740.
@article{3f2b102edfb643509aee538e2e078ea4,
title = "EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance",
abstract = "The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.",
keywords = "drug resistance, EGFR TKIs, non-small-cell lung cancer, pharmacology",
author = "Stefano Fogli and Beatrice Polini and {Del Re}, Marzia and Iacopo Petrini and Antonio Passaro and Stefania Crucitta and Eleonora Rofi and Romano Danesi",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/pgs-2018-0038",
language = "English",
volume = "19",
pages = "727--740",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - EGFR-TKIs in non-small-cell lung cancer

T2 - Focus on clinical pharmacology and mechanisms of resistance

AU - Fogli, Stefano

AU - Polini, Beatrice

AU - Del Re, Marzia

AU - Petrini, Iacopo

AU - Passaro, Antonio

AU - Crucitta, Stefania

AU - Rofi, Eleonora

AU - Danesi, Romano

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.

AB - The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.

KW - drug resistance

KW - EGFR TKIs

KW - non-small-cell lung cancer

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85047549824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047549824&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0038

DO - 10.2217/pgs-2018-0038

M3 - Review article

AN - SCOPUS:85047549824

VL - 19

SP - 727

EP - 740

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 8

ER -